Alison K. Cardenas

Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)

Ami V. Desai, Giles Robinson, Karen Gauvain et al. · Neuro-Oncology · 2022 · 121 citations · Full text

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Maura N. Dickler, Cristina Saura, Donald Richards et al. · Clinical Cancer Research · 2018 · 76 citations · Full text

Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Giles Robinson, Amar Gajjar, Karen Gauvain et al. · Journal of Clinical Oncology · 2019 · 60 citations

Pediatric Brain Tumors, Refractory Cns, Pathology +18

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

Roland Morley, Alison K. Cardenas, Peter G. Hawkins et al. · PLoS ONE · 2015 · 29 citations · Full text

Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.

Ami V. Desai, Giles Robinson, Ellen M. Basu et al. · Journal of Clinical Oncology · 2020 · 21 citations

Pediatric Brain Tumors, Cancer Management, Pathology +22